Assertio Therapeutics (ASRT) Tops Q3 EPS by 27c, provides guidance

Assertio Therapeutics (NASDAQ: ASRT) reported Q3 EPS of $0.18, $0.27 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $49.46 million versus the consensus estimate of $27.02 million.

GUIDANCE:

Assertio Therapeutics sees FY2025 revenue of $110-112 million, versus the consensus of $111.1 million.

For earnings history and earnings-related data on Assertio Therapeutics (ASRT) click here.

You May Also Be Interested In

• Waller: Recent Increases In Core Inflation Are Quite Broad
• First Advantage (FA) 6K contracts of July 22.50 calls trade
• Jefferies upgrades Shopify to Buy on AI commerce tailwinds, sees 30% upside